CTNM Insider Evert Schimmelpennink Buys 19,000 Shares

Evert Schimmelpennink Joins Executive Buying Wave

Contineum Therapeutics, Inc. (NasdaqGS: CTNM) saw additional insider activity on June 26, 2026, when entity Evert Schimmelpennink acquired 19,000 shares. This transaction took place as part of a wider group purchase among company leadership, reflecting simultaneous moves by multiple figures within the organization.

Coordinated Leadership Purchases at Contineum Therapeutics

The late-June purchasing round involved several key members of the organization stepping up to acquire shares on the exact same date. Troy Ignelzi picked up 19,000 shares on June 26, 2026. Sarah Boyce also added 19,000 shares on June 26, 2026. Olivia Ware bought 19,000 shares on June 26, 2026, and Todd Brady similarly acquired 19,000 shares on June 26, 2026. These transactions arrived alongside earlier disclosures highlighting parallel commitments from company insiders.

Stock Performance and Market Position

Shares of Contineum Therapeutics traded around $14.19 recently, placing the firm within its broader 52-week trading span that stretches from a low of $8.60 up to a high of $17.79. The biotechnology company carries a market capitalization of roughly $509.8 million. Its stock price sits near its 50-day moving average of $15.17 and above its 200-day moving average of $13.67.

Analysts Set New Price Targets

Financial institutions continue to adjust their outlooks on the healthcare firm as new research notes emerge. On July 31, 2026, RBC Capital maintained its outperform rating with a $23.00 price target, shifting from an earlier target of $22.00. Later, on September 15, 2026, Baird kept an outperform rating while moving its target to $19.00 from $20.00, and Jones Trading maintained a buy rating with a target of $24.00, down from $26.00. Morgan Stanley kept an equal-weight rating on September 28, 2026, setting its target at $17.00. More recently, on October 14, 2026, Baird lowered its stance to a neutral rating with a $14.00 target, down from $19.00. Jones Trading followed on October 15, 2026, by maintaining a buy rating and raising its target to $30.00 from $24.00. Across the board, the company holds a consensus strong buy rating with a mean target price of $22.57.

Inside the Biotechnology Pipeline

Contineum Therapeutics is a clinical-stage biopharmaceutical enterprise headquartered in San Diego, California. The company focuses on discovering and developing small-molecule therapies for neuroscience, inflammation, and immunology indications. Its primary pipeline assets include PIPE-791 for idiopathic pulmonary fibrosis and chronic pain, alongside PIPE-307 targeting depression and relapsing-remitting multiple sclerosis.

What to Watch at Contineum Therapeutics, Inc.

Observers will look toward the company's next scheduled earnings release on October 29, 2026, for operational updates and further financial details. Insider transactions are historical disclosures filed with the SEC and do not serve as indicators of future stock movements.